Publication

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET

Tamminga, M., Andree, K. C., Hiltermann, T. J. N., Jayat, M., Schuuring, E., van den Bos, H., Spierings, D. C. J., Lansdorp, P. M., Timens, W., Terstappen, L. W. M. M. & Groen, H. J. M., 7-Apr-2020, In : Cancers. 12, 4, 15 p., 896.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Tamminga, M., Andree, K. C., Hiltermann, T. J. N., Jayat, M., Schuuring, E., van den Bos, H., ... Groen, H. J. M. (2020). Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET. Cancers, 12(4), [896]. https://doi.org/10.3390/cancers12040896

Author

Tamminga, Menno ; Andree, Kiki C ; Hiltermann, T Jeroen N ; Jayat, Maximilien ; Schuuring, Ed ; van den Bos, Hilda ; Spierings, Diana C J ; Lansdorp, Peter M ; Timens, Wim ; Terstappen, Leon W M M ; Groen, Harry J M. / Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET. In: Cancers. 2020 ; Vol. 12, No. 4.

Harvard

Tamminga, M, Andree, KC, Hiltermann, TJN, Jayat, M, Schuuring, E, van den Bos, H, Spierings, DCJ, Lansdorp, PM, Timens, W, Terstappen, LWMM & Groen, HJM 2020, 'Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET', Cancers, vol. 12, no. 4, 896. https://doi.org/10.3390/cancers12040896

Standard

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET. / Tamminga, Menno; Andree, Kiki C; Hiltermann, T Jeroen N; Jayat, Maximilien; Schuuring, Ed; van den Bos, Hilda; Spierings, Diana C J; Lansdorp, Peter M; Timens, Wim; Terstappen, Leon W M M; Groen, Harry J M.

In: Cancers, Vol. 12, No. 4, 896, 07.04.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Tamminga M, Andree KC, Hiltermann TJN, Jayat M, Schuuring E, van den Bos H et al. Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET. Cancers. 2020 Apr 7;12(4). 896. https://doi.org/10.3390/cancers12040896


BibTeX

@article{c3f53032a0c74ae987b6015be5a90caf,
title = "Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch{\circledR} and ISET",
abstract = "Circulating tumor cells (CTCs) detected by CellSearch are prognostic in non-small-cell lung cancer (NSCLC), but rarely found. CTCs can be extracted from the blood together with mononuclear cell populations by diagnostic leukapheresis (DLA), therefore concentrating them. However, CellSearch can only process limited DLA volumes (≈2 mL). Therefore, we established a protocol to enumerate CTCs in DLA products with Isolation by SizE of Tumor cells (ISET), and compared CTC counts between CellSearch{\circledR} and ISET. DLA was performed in NSCLC patients who started a new therapy. With an adapted protocol, ISET could process 10 mL of DLA. CellSearch detected CTCs in a volume equaling 2 × 108 leukocytes (mean 2 mL). CTC counts per mL were compared. Furthermore, the live cell protocol of ISET was tested in eight patients. ISET successfully processed all DLA products-16 with the fixed cell protocol and 8 with the live cell protocol. In total, 10-20 mL of DLA was processed. ISET detected CTCs in 88{\%} (14/16), compared to 69{\%} (11/16, p < 0.05) with CellSearch. ISET also detected higher number of CTCs (ISET median CTC/mL = 4, interquartile range [IQR] = 2-6, CellSearch median CTC/mL = 0.9, IQR = 0-1.8, p < 0.01). Cells positive for the epithelial cell adhesion molecule (EpCAM+) per mL were detected in similar counts by both methods. Eight patients were processed with the live cell protocol. All had EpCAM+, CD45-, CD235- cells isolated by fluorescence-activated cell sorting (FACS). Overall, ISET processed larger volumes and detected higher CTC counts compared to CellSearch. EpCAM+ CTCs were detected in comparable rates.",
keywords = "DLA, CTC, NSCLC, liquid biopsy, biomarker, ISET, CellSearch, CTC FREQUENCY, BLOOD, IDENTIFICATION, CHALLENGES",
author = "Menno Tamminga and Andree, {Kiki C} and Hiltermann, {T Jeroen N} and Maximilien Jayat and Ed Schuuring and {van den Bos}, Hilda and Spierings, {Diana C J} and Lansdorp, {Peter M} and Wim Timens and Terstappen, {Leon W M M} and Groen, {Harry J M}",
year = "2020",
month = "4",
day = "7",
doi = "10.3390/cancers12040896",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET

AU - Tamminga, Menno

AU - Andree, Kiki C

AU - Hiltermann, T Jeroen N

AU - Jayat, Maximilien

AU - Schuuring, Ed

AU - van den Bos, Hilda

AU - Spierings, Diana C J

AU - Lansdorp, Peter M

AU - Timens, Wim

AU - Terstappen, Leon W M M

AU - Groen, Harry J M

PY - 2020/4/7

Y1 - 2020/4/7

N2 - Circulating tumor cells (CTCs) detected by CellSearch are prognostic in non-small-cell lung cancer (NSCLC), but rarely found. CTCs can be extracted from the blood together with mononuclear cell populations by diagnostic leukapheresis (DLA), therefore concentrating them. However, CellSearch can only process limited DLA volumes (≈2 mL). Therefore, we established a protocol to enumerate CTCs in DLA products with Isolation by SizE of Tumor cells (ISET), and compared CTC counts between CellSearch® and ISET. DLA was performed in NSCLC patients who started a new therapy. With an adapted protocol, ISET could process 10 mL of DLA. CellSearch detected CTCs in a volume equaling 2 × 108 leukocytes (mean 2 mL). CTC counts per mL were compared. Furthermore, the live cell protocol of ISET was tested in eight patients. ISET successfully processed all DLA products-16 with the fixed cell protocol and 8 with the live cell protocol. In total, 10-20 mL of DLA was processed. ISET detected CTCs in 88% (14/16), compared to 69% (11/16, p < 0.05) with CellSearch. ISET also detected higher number of CTCs (ISET median CTC/mL = 4, interquartile range [IQR] = 2-6, CellSearch median CTC/mL = 0.9, IQR = 0-1.8, p < 0.01). Cells positive for the epithelial cell adhesion molecule (EpCAM+) per mL were detected in similar counts by both methods. Eight patients were processed with the live cell protocol. All had EpCAM+, CD45-, CD235- cells isolated by fluorescence-activated cell sorting (FACS). Overall, ISET processed larger volumes and detected higher CTC counts compared to CellSearch. EpCAM+ CTCs were detected in comparable rates.

AB - Circulating tumor cells (CTCs) detected by CellSearch are prognostic in non-small-cell lung cancer (NSCLC), but rarely found. CTCs can be extracted from the blood together with mononuclear cell populations by diagnostic leukapheresis (DLA), therefore concentrating them. However, CellSearch can only process limited DLA volumes (≈2 mL). Therefore, we established a protocol to enumerate CTCs in DLA products with Isolation by SizE of Tumor cells (ISET), and compared CTC counts between CellSearch® and ISET. DLA was performed in NSCLC patients who started a new therapy. With an adapted protocol, ISET could process 10 mL of DLA. CellSearch detected CTCs in a volume equaling 2 × 108 leukocytes (mean 2 mL). CTC counts per mL were compared. Furthermore, the live cell protocol of ISET was tested in eight patients. ISET successfully processed all DLA products-16 with the fixed cell protocol and 8 with the live cell protocol. In total, 10-20 mL of DLA was processed. ISET detected CTCs in 88% (14/16), compared to 69% (11/16, p < 0.05) with CellSearch. ISET also detected higher number of CTCs (ISET median CTC/mL = 4, interquartile range [IQR] = 2-6, CellSearch median CTC/mL = 0.9, IQR = 0-1.8, p < 0.01). Cells positive for the epithelial cell adhesion molecule (EpCAM+) per mL were detected in similar counts by both methods. Eight patients were processed with the live cell protocol. All had EpCAM+, CD45-, CD235- cells isolated by fluorescence-activated cell sorting (FACS). Overall, ISET processed larger volumes and detected higher CTC counts compared to CellSearch. EpCAM+ CTCs were detected in comparable rates.

KW - DLA

KW - CTC

KW - NSCLC

KW - liquid biopsy

KW - biomarker

KW - ISET

KW - CellSearch

KW - CTC FREQUENCY

KW - BLOOD

KW - IDENTIFICATION

KW - CHALLENGES

U2 - 10.3390/cancers12040896

DO - 10.3390/cancers12040896

M3 - Article

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 896

ER -

ID: 122005986